Status:

COMPLETED

A Clinical Study to Assess the Effects of KB295 in Patients With Ulcerative Colitis (UC) on Gut Microbiota Structure and Function

Lead Sponsor:

Kaleido Biosciences

Conditions:

Ulcerative Colitis

Eligibility:

All Genders

18-75 years

Phase:

NA

Brief Summary

This exploratory, open-label clinical study aims to explore the effects of KB295, a novel glycan, on adult patients with ulcerative colitis (UC) presenting with mild-to-moderate UC symptoms

Eligibility Criteria

Inclusion

  • Be male or female, ≥18 and ≤75 years of age
  • Confirmed diagnosis of UC (\>6 months) by endoscopy
  • Mild-to-moderate UC with at least 4 weeks of UC symptomatology prior to screening
  • Stable medication regimen for at least 2 weeks prior to screening, if on medication for UC

Exclusion

  • Possible or confirmed diagnosis of Crohn's disease or indeterminate disease
  • History of isolated distal proctitis
  • Use of any antidiarrheal medications within the last 1 week prior to screening
  • Antibiotic treatment within the past 28 days prior to screening
  • Any non-UC related immunosuppressive medications other than purine analogs. Systemic corticosteroids including prednisone \> 10 mg per day are excluded.
  • Major intra-abdominal surgery related to the bowel within 24 weeks prior to the screening period and/or planned invasive surgery/hospitalization during the study
  • Major medical comorbidities, or other conditions in the opinion of the PI, that might impact the patient's safety or compliance, or the interpretation of the study results
  • Treatment with any other investigational drugs within 28 days prior to the screening visit

Key Trial Info

Start Date :

August 12 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 29 2021

Estimated Enrollment :

12 Patients enrolled

Trial Details

Trial ID

NCT04508413

Start Date

August 12 2020

End Date

November 29 2021

Last Update

January 24 2022

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Atlantia Food Clinical Trials

Chicago, Illinois, United States, 60611

2

Elligo Health Research, Inc.

Austin, Texas, United States, 78738

3

Atlantia Food Clinical Trials

Cork, Ireland, T23 R50R